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Stanford, CaliforniaABSTRACT Human familial hypertrophic cardiomyopathy is the most common Mendelian cardiovascular disease worldwide.
Among the most severe presentations of the disease are those in families heterozygous for the mutation R403Q in b-cardiac
myosin. Mice heterozygous for this mutation in the a-cardiac myosin isoform display typical familial hypertrophic cardiomyopathy
pathology. Here, we study cardiomyocytes from heterozygous 403/þ mice. The effects of the R403Q mutation on force-
generating capabilities and dynamics of cardiomyocytes were investigated using a dual carbon nanofiber technique to measure
single-cell parameters. We demonstrate the Frank-Starling effect at the single cardiomyocyte level by showing that cell stretch
causes an increase in amplitude of contraction. Mutant 403/þ cardiomyocytes exhibit higher end-diastolic and end-systolic
stiffness than þ/þ cardiomyocytes, whereas active force generation capabilities remain unchanged. Additionally, 403/þ cardi-
omyocytes show slowed relaxation dynamics. These phenotypes are consistent with increased end-diastolic and end-systolic
chamber elastance, as well as diastolic dysfunction seen at the level of the whole heart. Our results show that these functional
effects of the R403Q mutation are cell-intrinsic, a property that may be a general phenomenon in familial hypertrophic
cardiomyopathy.INTRODUCTIONFamilial hypertrophic cardiomyopathy (HCM) is the most
common Mendelian cardiovascular disease, affecting 1 in
500 people worldwide (1,2). HCM is defined as hypertrophy
of the heart that is unexplained by mechanical factors such
as hypertension or valve disease. This abnormal hypertrophy
is often accompanied by diminished cavity volume and
impaired relaxation (3). Clinical outcomes of HCM are
diverse, ranging from mild adjustments in lifestyle to severe
heart failure and early-onset sudden cardiac death (2,4,5).
To date, hundreds of mutations in multiple cardiomyocyte
sarcomeric genes have been identified (6). These mutations
cause alterations in proteins including those essential for
force production, namely b-cardiac myosin and actin, regu-
latory elements like tropomyosin and troponin, and those
primarily responsible for maintaining stability of the sarco-
mere, such as myosin-binding protein C.
The HCM mutation with one of the highest penetrance
and most severe clinical phenotypes is a missense mutation
in the b-cardiac myosin heavy chain gene that results in an
amino acid change from arginine to glutamine at position
403 (R403Q). This mutation occurs at a highly conserved
residue (7) in close proximity to the actin-binding interface
of the myosin motor domain (8). Patients with the R403Q
mutation have a high incidence of morbidity and early
mortality (4).
Although some information has been obtained on the
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(20–22), as well as at the whole heart level (23–26), only
one study so far has looked at contractility in R403Q heart
muscle cells (27) (cardiomyocytes). Investigating the effects
of the mutation at the single cardiomyocyte level has the
advantage of allowing us to determine which effects are
cell-intrinsic (i.e., a property of the cell independent of its
extracellular environment or interactions between the cells
as part of the native tissue) and to tease apart the con-
tributions of intracellular sarcomeric proteins and extracel-
lular fibrosis or neurohormonal influence to the disease.
Additionally, the use of intact cardiomyocytes allows us to
study the interaction of the sarcomeric proteins in their
native environment where they are highly ordered, and these
studies can be compared to in vitro studies with purified
proteins (28).
Although one ideally wants to study human cardiomyo-
cytes, several limitations exist in their availability. Human
biopsy samples, particularly those from HCM patients, are
difficult to obtain and additionally provide very low yields
(no more than 20%) of viable cardiomyocytes (29,30).
Although technologies for generating differentiated cardio-
myocytes from either human embryonic stem cells (31) or
induced-pluripotent stem cells (32,33) have been estab-
lished, they are still in their infancy. More importantly, these
cardiomyocyte differentiation technologies, at least for now,
are only able to generate cardiomyocytes that resemble the
immature state and fail to mature them to an adult cardio-
myocyte phenotype (34). Fortunately, a murine model is
available for the R403Q mutation, and the model does reca-
pitulate the HCM clinical phenotype (26). Hence, in thisdoi: 10.1016/j.bpj.2012.04.049
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which fully differentiated adult cardiomyocytes are readily
available.
Amousemodel of theHCM-causing R403Qmutationwas
established byGeisterfer-Lowrance et al. (26). It is important
to emphasize that although the mutation is in the predomi-
nant mouse a-cardiac myosin heavy chain isoform, these
mice do display typical HCM pathology. This is perhaps
not surprising, given that the mouse a-cardiac myosin heavy
chain is highly homologous to human b-cardiac myosin
heavy chain (92% identical overall, 100% identical for
30 amino acids flanking residue 403). Humans with cardio-
myopathies are generally heterozygous for the mutation,
and homozygous 403/403 mice do not survive past 1 week.
Adult heterozygous mice (403/þ, >15 weeks old) exhibit
cardiomyocyte hypertrophy, cellular disarray and fibrosis
(26), myofibrillar disarray (27), as well as diastolic dysfunc-
tion (23–25). These phenotypes are not usually seen in wild-
type (þ/þ) mice. Thus, this murine model of HCM can
provide useful insights into the effects of the R403Q muta-
tion on sarcomere function.
In a previously published study onR403Q cardiomyocytes
(27), the authors examined the unloaded contractile proper-
ties of single cardiomyocytes from adult heterozygous
403/þ mice that were placed on a regular glass coverslip
surface. We note that the close proximity of the cardiomyo-
cytes to the coverslip could potentially interfere with
contractility due to friction from the surface. Cardiomyo-
cytes can also adhere to glass surfaces with time, and hence
the contact of the cardiomyocytes with the coverslip at the
start of the experiment is variable, and can also vary during
the course of the experiment. Additionally, cardiomyocytes
contract against a variety of loads in vivo and hence the
absence of any loading on the cardiomyocytes in the experi-
ment is clearly unphysiological. To provide further insight
into the behavior of cardiomyocytes under more physiolog-
ical conditions, we used a dual carbon nanofiber setup (35)
to suspend single cardiomyocytes in solution, away from
the coverslip surface to minimize any interfering friction
during cell contraction. We compared the forces generated
by cardiomyocytes from þ/þ and 403/þ mice, as well as
the dynamics of contraction and relaxation. Most impor-
tantly, our setup allowed us to apply preload (stretch) to the
cardiomyocytes by moving the CFs apart, which enabled
us to determine the stiffness or elasticity of the cardiomyo-
cyte bothwhile relaxed (diastole) and atmaximal contraction
(systole). Application of preload also allows us to probe the
Frank-Starling effect at a single-cell level. The Frank-Star-
ling effect (36,37) is the ability of the heart to increase its
force of contraction and hence stroke volume in response
to an increase in the volume of blood filling the heart; at
the single-cell level this corresponds to an increase in active
contraction force generationwith increased preload (stretch).
We find that 403/þ cardiomyocytes have increased end-
diastolic as well as end-systolic stiffness compared to þ/þcardiomyocytes. However, the ability to generate increased
active force with increasing preload remains unchanged.
403/þ cardiomyocytes also showed slowed relaxation dyn-
amics compared to þ/þ cardiomyocytes. These findings at
the single-cell level are consistent with increased myocar-
dial elastance, both in diastole and systole, as well as
diastolic dysfunction (23–25) at the level of the whole heart
in 403/þ mice. This suggests that these functional effects of
the R403Q mutation are cell-intrinsic, a property that may
be a general phenomenon in HCM.METHODS AND MATERIALS
Animals
The mouse model of familial HCM used in this study contained an Arg to
Gln missense mutation at residue 403 of the mouse a-cardiac myosin heavy
chain (MHC) (26). Mouse genotypes were determined by restriction en-
zyme digestion of polymerase chain reaction-amplified tail DNA as previ-
ously described (26). Heterozygous male a-MHC403/þ and wild-type male
a-MHCþ/þ littermates were used for the study. All mice were maintained
according to protocols approved by the Administrative Panel on Laboratory
Animal Care of Stanford University.Cardiomyocyte isolation
Mice, 20–25 weeks old, were anesthetized with isoflurane (2%) and given
an intraperitoneal injection of heparin (200 units/mouse). Lack of withdraw
reflex with toe pinch was confirmed before proceeding. Hearts were excised
and promptly cannulated (within 70–90 s) via the aorta and Langendorff
perfused at a rate of 4 ml/min. Hearts were first perfused with main solution
(120.4 mM NaCl, 14.7 mM KCl, 0.6 mM KH2PO4, 0.6 mM Na2HPO4,
1.2 mMMgSO4, 4.6 mMNaHCO3, 10 mMHEPES, 30 mM taurine, 10 mM
2,3-butanedione monoxime and 5.5 mM glucose, pH 7.0) for 4 min, fol-
lowed by collagenase solution (main solution þ 600 units/ml Collagenase
Type 2, Worthington Biochemical, Lakewood, NJ) for 2 min, and finally
Ca2þ-collagenase solution (collagenase solution þ 50 mM CaCl2) for
6 min. During the last 1–2 min of perfusion, the Ca2þ-collagenase solution
was collected as it dripped off the heart, which was pale and flaccid by the
end of perfusion.
Ventricles were harvested and placed into the collected Ca2þ-collagenase
solution. The tissue was cut into small pieces with scissors and then further
dissociated by gentle pipetting through transfer pipettes. Stop solution 1
(main solution þ 10% fetal bovine serum (FBS) þ 12.5 mM CaCl2) was
added and the dissociated tissue was then poured through a mesh filter
into a 15 ml conical tube. Cells were allowed to sit for 5 min to allow
myocytes to settle by gravity before centrifuging at ~25  g (400 rpm in
Beckman Coulter Allegra 6R centrifuge with GH-3.8 rotor) for 3 min.
The supernatant was decanted and the cells were gently resuspended
in stop solution 2 (main solution þ 10% FBS þ 100 mM CaCl2). Settling,
centrifugation, and resuspension steps were repeated with stop solutions
3 and 4 (main solution þ 10% FBS þ 400 or 900 mM CaCl2, respectively),
and finally with contractility buffer (137 mMNaCl, 20 mMHEPES, 15 mM
glucose, 5.4 mM KCl, 1.3 mM MgCl2, 1.2 mM NaH2PO4, 1 mM CaCl2).
Isolations consistently yielded >40% rod-shaped cardiomyocytes with
clear sarcomeric banding patterns. Experiments were conducted within
6 h of excision of hearts from mice.Cell attachment and contractility measurements
All measurements were performed on a modified Myocyte Contractility
System (IonOptix, Milton, MA). An add-on to the system (similar to thatBiophysical Journal 102(12) 2782–2790
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carbon fibers (CFs) mounted in glass capillaries using hydraulic manipula-
tors (Siskiyou, Grants Pass, OR) and piezo translators (Physik Instruments,
Karlsruhe, Germany). CFs (12–14 mm in diameter) were generous gifts
from Christian Bollensdorf and Peter Kohl at Imperial College London.
All contractility measurements were performed at 37C in contractility
buffer. Cells were placed at extremely low concentrations in a voltage-
stimulation chamber with poly-HEMA (2-hydroxyethyl methacrylate,
Sigma-Aldrich, St. Loius, MO) coated coverslips to prevent adhesion to
the coverslip surface. Criteria used for selection of cardiomyocytes for
experiments were i), rod-shaped, ii), clear and organized sarcomeres, iii),
sarcomere lengths in the range of 1.6–1.85 mm, iv), bleb- and ruffle-free
membranes, v), consistent ~4–5% sarcomere shortening upon voltage stim-
ulation before attachment of CFs, and vi), absence of spontaneous contrac-
tions when unstimulated, throughout the course of the experiment. These
cardiomyocytes would fall primarily under ‘‘type I’’ according to the clas-
sification defined by Kim et al. (27). Non-type I cardiomyocytes frequently
exhibited spontaneous contractions in the absence of stimulation, resulting
in data that were unreliable. The selected cardiomyocyte was subject to
field voltage stimulation (paced) at 1 Hz while the two CF tips were lightly
pressed down in succession, at a distance of 55–60 mm from each other.
Initial adhesion was verified by lifting the CFs vertically; CFs with cardio-
myocyte attached were subsequently returned to the surface, and pacing
continued for at least 3 min to allow enhancement of adhesion. Finally, car-
diomyocytes were lifted ~5–10 mm off the coverslip surface.
While the cell was suspended between the two CFs away from the cover-
slip surface and before application of any preload, measurements of resting
length parameters were taken. Preload was then applied by axial stretch of
the cell during diastole, in 2–4 mm step increments. The positions of
the CFs were controlled by piezo translators and custom MATLAB
(The MathWorks, Natick, MA) software, courtesy of Peter Lee from the
Kohl lab. The cell was returned to resting length between each level of
preload. Upon completion of measurements, CFs were lifted out of the
solution, which caused the cell or any cell debris to be pulled off the CFs
by surface tension. CFs could then be reused.FIGURE 1 Schematic of forces measured in cardiomyocyte-contractility
experiments. (a) At resting length in diastole, the distance between two
CFs at piezo translators (CFD0) and at the cell-attached CF tips (initial
end-diastolic length, EDL0) are equal. Force is zero. (b) Upon contraction
in systole, the distance betweenCF tips decreases (initial end-systolic length,
ESL0). The force is the product of the average stiffness of the CFs (kave) and
the distance that the CFs are bent (CFD0-ESL0). (c) Preload is applied by
moving the piezo-translator mounted CFs apart to length CFD1. Cell-
attached CF tips also move apart but to a lesser extent, to length EDL1.
The passive force exerted by the cardiomyocyte is FP ¼ kave(CFD1-EDL1).
(d) Contraction under preload moves the CF tips to length ESL1, making
the total force exerted FT ¼ kave(CFD1-ESL1). (e) Representative trace of
changes in distance between cell-attached CF tips (effective cell length) as
the cardiomyocyte contracts at a rate of 1 Hz. (f) Normalization of force to
cross-sectional area of the cardiomyocyte gives changes in contractile force
per area, from which dynamic parameters can be determined.Data analysis
Initial analysis of the contractility data was performed using IonWizard
software (IonOptix LLC) andMATLAB. For each cell, at least three contrac-
tion traces per level of preload were analyzed individually, and these tripli-
cate values were then averaged to obtain parameter values for the cell.
Mean5 SE was then calculated across all cells for each condition. Forces
were calculated from the average stiffness of the two CFs multiplied by
CF bending. CF stiffness (0.050.20 mN mm1) was measured using a force
transducer system, courtesy of C. Bollensdorf. CF bending is the distance
between the CF holders minus the distance between the CF tips. End-
diastolic (passive) and end-systolic (total) forces were obtained for each
preload level and normalized to the cross-sectional area of each cell. The
cardiomyocytes were assumed to be ellipsoidal in cross section, with
a short-to-long axis ratio of 1:3 (38). End-diastolic force length relation
(EDFLR) and end-systolic force length relation (ESFLR) were obtained
by performing linear least squares regressions to the end-diastolic and end-
systolic points, respectively. Care was taken not to include points beyond
cell lengths at which the force-length relationship was no longer linear.
Over the length range studied, the assumption was made that the slopes of
EDFLR and ESFLR are independent of the mode of contraction (35).
The maximum rates of force development during contraction (dF/dtmax,C)
and force reduction during relaxation (dF/dtmax,R) were similarly normal-
ized to the cross-sectional area of each cell. The preload dependence of
these rates was obtained by grouping the data into bins of size ~5% of
ESL0, from which errors in rates as well as normalized effective cell length
were calculated. The preload dependence of the time taken to return
halfway from systole to diastole during relaxation (t50,R) was analyzed in
the same way.Biophysical Journal 102(12) 2782–2790RESULTS
Preload application experimental approach
Fig. 1 illustrates the forces measured during different stages
of the loading protocol. Force is calculated as the product of
the average stiffness of the two CFs (kave) and the total
distance that the CFs are bent. At resting length (no preload)
and while relaxed, or in diastole (Fig. 1 a), the distance
between the two CFs at the piezo translators (initial carbon
fiber distance, CFD0) and at the cell-attached ends (initial
end-diastolic length, EDL0) are equal. This distance, EDL0
was kept to 55–60 mm to standardize, as far as possible across
cells, the number of sarcomeres between the CFs that
contribute to their bending. Initial diastolic force is hence
zero. At maximal contraction, or in systole (Fig. 1 b),
the distance at the CF tips is reduced to ESL0 (initial end-
systolic length), and the maximum force generated by the
TABLE 1 Cardiomyocyte behavior at resting length
þ/þ 403/þ
n (cells, animals) 14, 5 15, 6
Resting cell length (mm) 1265 6 1315 6
Resting sarcomere length (mm) 1.745 0.02 1.685 0.02
Cell width (mm) 20.75 0.6 20.15 0.5
Systolic Parameters
Time to systole (ms) 1125 6 1175 5
Systolic force/area (mN/mm2) 1.335 0.15 1.335 0.11
dF/dtmax,C/area (mN/[s mm
2]) 25.65 3.4 24.95 2.3
Diastolic Parameters
t50,R (ms) 38 5 3* 725 7*
dF/dtmax,R/area (mN/[s mm
2]) 16.95 1.9* 11.25 1.3*
Data are shown as mean5 SE.
dF/dtmax,C/area: Maximum rate of force development during contraction
normalized to cross-sectional area.
t50,R: Time taken to return halfway from systole to diastole during
relaxation.
dF/dtmax,R/area: Maximum rate of force reduction during relaxation
normalized to cross-sectional area.
*Significantly different between þ/þ and 403/þ by two-tailed unpaired
t-test, p < 0.05.
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apply preload (Fig. 1, c and d), the piezo translators are
moved apart to lengthCFD1. In diastole, (Fig. 1 c) the stretch-
ing of compliant elements such as titin (39,40) within the
cardiomyocyte exerts a passive force or tension on the CFs,
bending the CFs a total distance of (CFD1-EDL1). The
passive force in diastole is thus FP ¼ kave(CFD1-EDL1). In
systole, the cardiomyocyte exerts an active contractile force,
bringing the CF tips to a distance of ESL1. Here, the total
force generated by the cardiomyocyte is FT ¼ kave(CFD1-
ESL1). The active force generated by the cardiomyocyte is
therefore FA ¼ FTFP. Increasing preload can be applied
by further axial stretch of the cardiomyocyte, with returns
to resting length between each level of preload.
A representative trace of changes in distance between
cell-attached CF tips (hereafter referred to as effective cell
length) as the cardiomyocyte contracts at a rate of 1 Hz
is shown in Fig. 1 e. To allow comparison across cells
and animals, contractile force is normalized to the cross-
sectional area of the cardiomyocyte, which is assumed to
be ellipsoidal with a short-to-long axis ratio of 1:3 (38).
From the dynamic changes in this normalized contractile
force (Fig. 1 f), parameters such as the normalized maximum
rate of force development during contraction (dF/dtmax,C/
area) and the normalized maximum rate of force reduction
during relaxation (dF/dtmax,R/area) can be determined.At resting length, 403/D cardiomyocytes have
slowed relaxation rates compared to D/D
cardiomyocytes
We began by observing the behavior of wild-type (þ/þ)
cardiomyocytes and cardiomyocytes heterozygous for the
hypertrophic cardiomyopathy mutation R403Q (403/þ) at
resting length, before application of preload (Table 1).
Resting cell lengths, sarcomere lengths, and cell widths
were similar for both groups. Parameters describing cardio-
myocyte contraction, namely the time to systole, the
normalized systolic force as well as the normalized maxi-
mum rate of force development during contraction (dF/
dtmax,C/area) did not differ significantly between þ/þ and
403/þ cardiomyocytes. However, for cardiomyocyte relax-
ation parameters, we observed that the time taken to return
halfway from systole to diastole during relaxation (t50,R) as
well as the normalized maximum rate of force reduction
during relaxation (dF/dtmax,R/area) at resting length were
significantly slower in 403/þ cardiomyocytes, indicative
of diastolic dysfunction.403/D cardiomyocytes have higher end-diastolic
and end-systolic stiffness compared to D/D
cardiomyocytes
We next studied the response of the cardiomyocytes to pre-
load. Fig. 2 a shows a representative trace of effective celllength changes as increasing levels of preload were applied.
Initially, the cardiomyocyte was at resting length, and
transitioned from EDL0 in diastole (blue line and dot,
time segment R) to ESL0 in systole (red line and dot, time
segment R). Increasing levels of preload was applied from
time segments P1 to P4, with corresponding end-diastolic
lengths shown in blue and end-systolic lengths in red.
The increase in the amplitude of contraction (the dif-
ference between end-diastolic and end-systolic lengths)
demonstrates the Frank-Starling effect at the level of the
single cell.
End-diastolic and end-systolic forces were calculated as
described in Fig. 1, normalized to the cardiomyocyte
cross-sectional area and plotted against effective cell length
normalized to EDL0, yielding the data points in Fig. 2 b
(labels in Fig. 2 b correspond to those in Fig. 2 a). The
end-diastolic points (blue circles) describe a linear depen-
dence of passive force on cell length, a dependence known
as the end-diastolic force-length relation (EDFLR, blue
line). The slope of EDFLR is a measure of the passive
stiffness or elasticity of the cardiomyocyte (end-diastolic
stiffness), a property likely conferred by the presence of
compliant elements in the cell that resist stretching. A linear
dependence is similarly described by the end-systolic points
(red circles), giving the end-systolic force-length relation
(ESFLR, red line), which indicates the total force the cardi-
omyocyte is able to produce at each level of preload. The
slope of ESFLR is a measure of the stiffness of the cardio-
myocyte at maximal contraction (end-systolic stiffness).
The end-diastolic points and average EDFLR slopes
(Fig. 2 c, Table 2) indicate that 403/þ cardiomyocytes (open
circles, dotted line; slope ¼ 0.36 mN/mm2) have signifi-
cantly higher end-diastolic stiffness compared toþ/þ cardi-
omyocytes (solid circles, solid line; slope¼ 0.22 mN/mm2).Biophysical Journal 102(12) 2782–2790
FIGURE 2 403/þ cardiomyocytes have higher
end-diastolic and end-systolic stiffness. (a) Repre-
sentative data of effective cell lengthmeasurements
(distance between the CF tips at the cell-attached
end) of a cardiomyocyte undergoing voltage stimu-
lation and contraction at 1 Hz, with the application
of preload. Initially, the cell is at resting length
(time segment R); increasing levels of preload are
applied from time segments P1–P4. Dotted lines
and dots indicate end-diastolic (blue) and end-
systolic (red) lengths, respectively, and correspond
to EDL and ESL in Fig. 1. (b) End-diastolic (blue)
and end-systolic (red) points at rest (R) and per
level of preload (P1–P4) are plotted as normalized
force against normalized effective cell length.
End-diastolic force-length relation (EDFLR, blue)
and end-systolic force-length relation (ESFLR,
red) are obtained from linear regressions of end-
diastolic and end-systolic points, respectively. (c)
EDFLRs of þ/þ (solid circles, solid lines) and
403/þ (open circles, dotted lines) cardiomyocytes.
The slope of EDFLR for 403/þ cardiomyocytes
(0.36 mN/mm2) is steeper than that for þ/þ cardi-
omyocytes (0.22 mN/mm2), indicating that 403/þ
cardiomyocytes have higher end-diastolic stiffness.
(d) Similarly, ESFLR of 403/þ cardiomyocytes
(slope ¼ 0.50 mN/mm2) is steeper than that
for þ/þ cardiomyocytes (slope ¼ 0.37 mN/mm2),
indicating higher end-systolic stiffness.
2786 Chuan et al.The same trend is seen for end-systolic points and
average ESFLR slopes (Fig. 2 d, Table 2; 403/þ slope ¼
0.50 mN/mm2; þ/þ slope ¼ 0.37 mN/mm2), indicating
higher end-systolic stiffness of 403/þ cardiomyocytes.Active force generation of 403/D cardiomyocytes
is the same as D/D cardiomyocytes
It is important to note that ESFLR describes preload depen-
dence of total force, which consists of two components—
passive force and active force. As mentioned before, passive
force is primarily a result of resistance from compliant
cellular elements being stretched. Active force, on the other
hand, is primarily generated by the Ca2þ-regulated and
energy-dependent sliding of actin filaments along myosin
in the cardiomyocyte sarcomeres, resulting in contraction.
It is the increase in amplitude of this active force componentTABLE 2 Measures of passive, total, and active force
þ/þ 403/þ
Passive force, FP
EDFLR slope (mN/mm2) 0.225 0.02* 0.365 0.04*
Total force, FT
ESFLR slope (mN/mm2) 0.375 0.03* 0.505 0.05*
Active force, FA
ESFLR – EDFLR slope (mN/mm2) 0.155 0.05 0.145 0.09
FSG Index 1.615 0.09 1.455 0.06
Data are shown as mean5 SE.
*Significantly different between þ/þ and 403/þ by two-tailed unpaired
t-test, p < 0.05.
Biophysical Journal 102(12) 2782–2790with preload that is the Frank-Starling effect (41), and as
described earlier is seen in the increase in amplitude of
contraction with cell stretch (Fig. 2 a). The contribution of
the active force to the total force of contraction may be
teased apart in two ways. We can look at the difference in
slopes between ESFLR and EDFLR, which gives the depen-
dence of the normalized active force component on preload.
This value is 0.15 mN/mm2 for þ/þ cardiomyocytes and
0.14 mN/mm2 for 403/þ cardiomyocytes (Table 2). Alterna-
tively, the use of the Frank-Starling Gain (FSG) index,
defined as the ratio of the slopes of ESFLR and EDFLR,
has been proposed to be useful as a dimensionless descriptor
of active force recruitability (41). This index basically
expresses the active force component as a multiple of the
passive force at each preload. The FSG Index is 1.61
for þ/þ cardiomyocytes and 1.45 for 403/þ cardiomyo-
cytes (Table 2). Neither the difference in slopes between
ESFLR and EDFLR nor the FSG Index is significantly
different between the two groups of cardiomyocytes. Hence,
it appears that although 403/þ cardiomyocytes have higher
end-diastolic and end-systolic stiffness and greater overall
force production, active force generation is unchanged.Slowed relaxation of 403/D cardiomyocytes
compared to D/D cardiomyocytes is consistent
across preloads studied
We analyzed the dynamics of contraction and relaxation
across different preloads. The normalized maximum rate
Effects of R403Q Mutation in Cardiomyopathy 2787of force development during contraction of 403/þ cardio-
myocytes (Fig. 3 a, open circles, dotted line), while
possibly reduced by ~10%, was similar to þ/þ cardiomyo-
cytes (Fig. 3 a, solid circles, solid line) across preloads
studied. The normalized maximum rate of force reduction
during relaxation, however, was consistently slower in
403/þ cardiomyocytes by a significant amount (Fig. 3 b).
This slowed relaxation was also evident in a considerably
longer t50,R, which is the time taken to return halfway
from systole to diastole (Fig. 3 c), for 403/þ cardiomyocytes
across studied preloads.DISCUSSION
In this work, we used a dual carbon nanofiber technique to
investigate the effects of the R403Q familial hypertrophic
cardiomyopathy mutation at the single cardiomyocyte level.
The use of isolated cardiomyocytes has allowed us to
identify the effects of hypertrophic cardiomyopathy that
are inherent in the cardiomyocyte itself, as contributions
from extracellular fibrosis or neurohormonal influences
are absent. To our knowledge, this is the first study to ex-
amine in detail the preload-dependent contractile properties
of single cardiomyocytes bearing a HCM mutation. Impor-
tantly, the application of preload has allowed us to measure
the end-diastolic and end-systolic stiffness of cardiomyo-
cytes, and also investigate the Frank-Starling effect at the
level of single cells (35,41).
Investigating the effects of the mutation at the single
cardiomyocyte level has allowed us to isolate and identify
the cell-intrinsic contributions of intracellular factors to
disease, which cannot easily be done at the tissue or whole
heart level because these are complicated by effects from
extracellular factors such as fibrosis and hormones. Studies
done on whole mouse hearts either in vivo (23,24,42) or
in isolated heart preparations (25) have shown increased
passive elastance and end-systolic elastance in 403/þ
mice compared to þ/þ mice. Similarly, at the tissue level,
isolated papillary muscle strips (20) and myocardial strips
(22) from 403/þ mice demonstrated increased passive
stiffness and increased maximum total force respectively.
The increased end-diastolic and end-systolic stiffness thatwe see in 403/þ single cardiomyocytes are consistent with
the characteristics seen at the whole heart and tissue level.
Additionally, diastolic dysfunction manifest as slowed
maximal rates of pressure reduction and increased time to
peak filling is observed in whole 403/þ hearts (23,24,42).
The slowed relaxation dynamics that we observe for isolated
403/þ cardiomyocytes are again in agreement with the
properties of the whole heart in 403/þ mice. This suggests
that these hallmarks of human HCM, namely increased
passive and end-systolic chamber elastance and slowed
cardiac relaxation (3,43), do not require the presence of
extra-cardiomyocyte factors to explain them, and may be
cell-intrinsic and inherent in the cardiomyocytes. Cardiac
morphology and histological changes that occur with
disease progression such as chamber wall thickening and
interstitial fibrosis (44) most likely exacerbate these
phenotypes.
Multiple studies have been done with rodent and human
cardiac myosin containing the R403Q mutation expressed
in and purified from a variety of sources such as insect cells
(17,18), mammalian cells (16), transgenic mouse models
(10,13,14,19), and human soleus and cardiac biopsies
(9,15). Here, we consider only the most relevant studies
done with a-cardiac myosin purified from R403Q mouse
hearts (10,13,14,19). At the single molecule level, the
average unitary displacement and force of R403Q myosin
purified from homozygous 403/403 mouse hearts are
unchanged (19) compared to myosin purified from þ/þ
mouse hearts. However, the duty ratio of R403Q myosin
is increased as a result of ~1.4–2.2 increased Vmax rates
in actin-activated ATPase assays (14,19), and 1.25–1.50
increased actin translocation velocities (vactin) measured
by in vitro motility assays (10,13,19). This increased duty
ratio is consistent with a ~2.2 increased average isometric
force generation seen in ensemble myosin assays (10,19).
The increase in duty ratio of R403Q myosin would
predict that both the active force and total force produced
by 403/þ cardiomyocytes are increased. Although we
observe an increased total force production, this is due
primarily to the increased passive force. No significant
increase in preload-dependent active force generation, or
the Frank-Starling effect, is seen in 403/þ cardiomyocytes.FIGURE 3 403/þ cardiomyocytes have slowed
rates of relaxation compared to þ/þ cardiomyo-
cytes across all preloads studied. (a) Normalized
maximum rates force development during contrac-
tion, dF/dtmax,C/area for þ/þ (solid circles, solid
lines) and 403/þ (open circles, dotted lines) cardi-
omyocytes are similar across all preloads. (b)
Normalized maximum rates force reduction during
relaxation, dF/dtmax,R/area are consistently slower
for 403/þ compared to þ/þ cardiomyocytes
across all preloads. (c) The time taken to return
halfway from systole to diastole, t50,R is greater
for 403/þ cardiomyocytes than þ/þ cardiomyo-
cytes across all preloads.
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increase in active force is balanced by a reduced efficiency
of force production due to myofibrillar disarray (27),
disorder at the myosin-actin interface (8), or disrupted coor-
dination between the two myosin heads (19) as a result of
the R403Q mutation. Although the 403/þ cardiomyocytes
used in our assays do not show gross myofibrillar disarray
by eye, it is likely that some disorganization is present at
the molecular level.
Myofibrillar disarray (27) could also account for the
increased cardiomyocyte passive stiffness that we observe
in 403/þ cardiomyocytes. The disruption of the regular
parallel arrangement and crystalline organization of myofil-
aments could increase the resistance of compliant elements
within the disorganized myofibrils to stretching. An alterna-
tive explanation could be the decreased elastance of titin, the
primary determinant of passive stiffness, in 403/þ cardio-
myocytes. Protein kinase C-a (PKC-a) has been implicated
in and shown to be upregulated in hypertrophy (45–48), and
phosphorylation of titin’s PEVK spring element by PKC-a
has been reported to increase titin-based passive tension in
myocardial tissue (49,50). Although neither phenomenon
has been directly demonstrated in HCM, this PKC-a-
dependent increase in titin-based passive tension is a pro-
bable mechanism given the myocardial and cardiomyocyte
hypertrophy evident in HCM. The exact molecular mecha-
nism by which the R403Q mutation causes an increase in
cardiomyocyte passive stiffness remains to be uncovered.
A previous study on the contractile properties of 403/þ
cardiomyocytes reported a reduced maximum rate of
decrease in cell length during contraction (27) compared
to þ/þ cardiomyocytes. Although a slight impairment of
contraction dynamics in 403/þ cardiomyocytes is observed
in our study (Fig. 3 a), it is to a lesser extent than previously
reported. It is possible that frictional or weak adhesion
effects from the cover slip surface in the earlier study or
differences in data normalization could account for the dis-
crepancy. Another possible reason could be the selection of
primarily rod-shaped, type I cardiomyocytes for our study,
as contraction velocity was less impaired in rod-shaped car-
diomyocytes compared to other populations of cardiomyo-
cytes (27).
The diastolic dysfunction that we observe in 403/þ cardi-
omyocytes (confirming a previous report (27)) may be ratio-
nalized by changes in affinity of R403Q cardiac myosin for
regulated actin filaments. Although in vitro ATPase and
motility assays generally show increased Km and hence
decreased affinity of R403Qmyosin for unregulated purified
actin filaments (19), the use of regulated tropomyosin-
troponin-actin filament complexes, better reflecting condi-
tions in the cardiomyocyte, instead gives a decrease in Km
and increased apparent affinity of R403Q myosin for these
regulated actin filaments (14). This increased affinity of
R403Q myosin for regulated actin, in addition to its in-
creased duty ratio, may cause the R403Q myosin populationBiophysical Journal 102(12) 2782–2790in 403/þ cardiomyocytes to exert a greater drag on the actin
filaments during relaxation, resulting in the observed dia-
stolic dysfunction.
Increased expression of the fetal cardiac myosin isoform
has been shown to occur in cardiac hypertrophy in both
humans and rodents (51). In 403/þ mice, this increase in
b-cardiac myosin proportion occurs no earlier than 20 weeks
of age, as the myosin isoform profiles of 10–20 week
old þ/þ and 403/þ mice have been shown to be similar
(22). Additionally, at the level of the whole heart, increased
chamber elastance and diastolic dysfunction is already
evident in young, 5–6-week-old 403/þ mice (23,26), an
age at which any increase in b-cardiac myosin proportion
or significant fibrosis is unlikely to have occurred. These
functional effects are hence likely due to the presence of
R403Q a-cardiac myosin. At older ages, such as in our
study, the cell-intrinsic functional effects seen in 403/þ
cardiomyocytes are similarly due at least partially, if not
primarily to R403Q a-cardiac myosin.
Although the HCM-causing mutation being studied is in a
sarcomeric protein, we do not rule out the possibility that the
phenotypes observed are caused by secondary effects on
Ca2þ handling in the 403/þ cardiomyocyte. Cardiomyocyte
relaxation kinetics is importantly affected by the rate of
Ca2þ reuptake into the sarcoplasmic reticulum (SR). 403/þ
cardiomyocytes have been shown to exhibit delayed rates
of Ca2þ reuptake into the SR (27), which may be a result
of reduced levels of the SR Ca2þ-binding protein calseques-
trin (42). Additionally, reduced levels (42) of SR Ca2þ but
normal cytosolic Ca2þ levels (52) in 403/þ cardiomyocytes
at rest suggest that the mutant cardiomyocytes may display
enhanced Ca2þ retention in the sarcomere. These ob-
servations are all consistent with defects in Ca2þ handling
in 403/þ cardiomyocytes that may result in diastolic
dysfunction.
In conclusion, we have demonstrated the use of the dual
carbon nanofiber technique and application of preload in
probing sarcomeric functions that may be altered as a result
of mutations. Much work remains to be done in elucidating
the exact mechanisms by which the R403Q mutation results
in the phenotypes observed. Additionally, the cell-autonomy
of these hallmark HCM phenotypes may be a general
phenomenon in HCM, a testable hypothesis with multiple
animal models of HCM available (53–57). Potential phar-
macological agents for HCM may be tested using CF tech-
niques similar to the one described here because it is likely
that therapies that alleviate these cell-intrinsic sarcomeric
dysfunctions at the cardiomyocyte level will also have posi-
tive effects in vivo. Finally, as advances in generating well-
differentiated human cardiomyocytes in vitro are underway,
it may soon be possible to explore the functional effects of
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